UK Space Agency partners with BiologIC Technologies for drug manufacturing

The UK Space Agency (UKSA) has partnered with BiologIC Technologies to develop new technologies for drug manufacturing trials aboard the International Space Station.

According to BiologIC, a robust, expandable, and partially automated bio-processing infrastructure is needed for the harsh environment of space.

The company stated that it has created an accurate bio-processing platform that works in microgravity.

UKSA and BiologIC plan to develop a bio-processing platform capable of operating in the low Earth orbit and space environment’s microgravity.

Space-based bio-manufacturing has become a critical strategy for countries worldwide to sustain human activities in space, with bio-pharmaceutical companies developing new therapeutic values under microgravity conditions.

BiologIC intends to experiment with its bio-computer technology in space. Bio-computers are a new category of machines made from liquid bio-processing chips, similar to computer chips.

Advanced biotechnology enterprises are rapidly adopting this technology to work on cellular, genetic, antibody, ADC, RNA-LNP, and stem cell therapies.

The UK Space Agency will invest $84 million in this project.

Leave a Reply

Your email address will not be published. Required fields are marked *